SG11201400513PA
(en)
|
2011-09-08 |
2014-06-27 |
Yeda Res & Dev |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
KR102135239B1
(en)
|
2012-08-20 |
2020-07-17 |
프레드 헛친슨 켄서 리서치 센터 |
Method and compositions for cellular immunotherapy
|
MY190711A
(en)
|
2013-02-20 |
2022-05-12 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
TWI654206B
(en)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
RU2718542C2
(en)
|
2014-04-07 |
2020-04-08 |
Новартис Аг |
Treating a malignant tumor using a chimeric antigen cd19 receptor
|
CN106536558A
(en)
*
|
2014-04-10 |
2017-03-22 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Transgene genetic tags and methods of use
|
SG10201808491UA
(en)
|
2014-04-16 |
2018-11-29 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
US11400115B2
(en)
|
2014-04-23 |
2022-08-02 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
SI3134432T1
(en)
*
|
2014-04-25 |
2021-01-29 |
Bluebird Bio, Inc. |
Mnd promoter chimeric antigen receptors
|
CN106793780B
(en)
|
2014-06-06 |
2020-05-26 |
蓝鸟生物公司 |
Improved T cell compositions
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
SG10201913782UA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
MX2017001008A
(en)
|
2014-07-21 |
2017-08-02 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor.
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
CA2956385A1
(en)
*
|
2014-07-25 |
2016-01-28 |
Theravectys |
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
|
US10752684B2
(en)
|
2014-07-29 |
2020-08-25 |
Cellectis |
ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
|
EP3194432B1
(en)
*
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
CA2958757C
(en)
|
2014-08-19 |
2021-04-27 |
Miltenyi Biotec Gmbh |
Chimeric antigen receptor specific for ssea4 antigen
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
TWI751102B
(en)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
Antibodies and chimeric antigen receptors specific for cd19
|
EP3189073B1
(en)
|
2014-09-04 |
2019-12-25 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
BR112017005390A2
(en)
|
2014-09-17 |
2017-12-12 |
Novartis Ag |
target cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA2961654A1
(en)
*
|
2014-09-19 |
2016-03-24 |
City Of Hope |
Costimulatory chimeric antigen receptor t cells targeting il13r.alpha.2
|
KR20170068504A
(en)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
EP3932950A1
(en)
|
2014-10-20 |
2022-01-05 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
RS60685B1
(en)
|
2014-11-05 |
2020-09-30 |
Juno Therapeutics Inc |
Methods for transduction and cell processing
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
WO2016090190A1
(en)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
WO2016094873A2
(en)
*
|
2014-12-12 |
2016-06-16 |
Emergent Product Development Seattle, Llc |
Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
|
HRP20211648T1
(en)
|
2014-12-12 |
2022-02-04 |
2Seventy Bio, Inc. |
Bcma chimeric antigen receptors
|
KR20170093254A
(en)
|
2014-12-29 |
2017-08-14 |
노파르티스 아게 |
Methods for producing chimeric antigen receptor-expressing cells
|
MA41346A
(en)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
POST-TRANSCRIPTIONAL REGULATORY ELEMENTS OF MODIFIED HEPATITIS
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
CN105985444B
(en)
*
|
2015-02-05 |
2024-02-13 |
博生吉安科细胞技术有限公司 |
Chimeric antigen receptor, and method and application for rapidly constructing chimeric antigen receptor
|
SI3280729T1
(en)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
EP4234685A3
(en)
|
2015-04-17 |
2023-09-06 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
KR102434330B1
(en)
|
2015-05-01 |
2022-08-22 |
더 리전츠 오브 더 유니버시티 오브 캘리포니아 |
Glycan-dependent immunotherapeutic molecules
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
TW201706300A
(en)
|
2015-05-20 |
2017-02-16 |
瑟勒提斯公司 |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
EP3303381A1
(en)
|
2015-05-29 |
2018-04-11 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
JP6949728B2
(en)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
WO2017009852A1
(en)
|
2015-07-16 |
2017-01-19 |
Yeda Research And Development Co. Ltd. |
Use of anti third party central memory t cells
|
CA2992989A1
(en)
*
|
2015-07-21 |
2017-01-26 |
City Of Hope |
T cells for expression of chimeric antigen receptors and other receptors
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
EP3328399B1
(en)
|
2015-07-31 |
2023-12-27 |
Regents of the University of Minnesota |
Modified cells and methods of therapy
|
US11458167B2
(en)
*
|
2015-08-07 |
2022-10-04 |
Seattle Children's Hospital |
Bispecific CAR T-cells for solid tumor targeting
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
CN106467906B
(en)
*
|
2015-08-20 |
2019-09-27 |
北京马力喏生物科技有限公司 |
Construct, transgenosis lymphocyte and its preparation method and application
|
AU2016315704B2
(en)
*
|
2015-08-31 |
2022-08-11 |
Helixmith Co., Ltd |
Anti-sialyl Tn chimeric antigen receptors
|
EP3344996A2
(en)
|
2015-09-03 |
2018-07-11 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
JP6959909B2
(en)
|
2015-09-09 |
2021-11-05 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
Genetic recombination of macrophages for immunotherapy
|
KR20180049080A
(en)
*
|
2015-09-11 |
2018-05-10 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
Biologically related orthogonal cytokine / receptor pairs
|
CN108289954B
(en)
|
2015-09-24 |
2022-05-31 |
阿布维特罗有限责任公司 |
HIV antibody compositions and methods of use
|
CN113774495A
(en)
|
2015-09-25 |
2021-12-10 |
阿布维特罗有限责任公司 |
High throughput method for T cell receptor targeted identification of naturally paired T cell receptor sequences
|
CN115074331A
(en)
*
|
2015-10-06 |
2022-09-20 |
希望之城公司 |
Chimeric antigen receptor targeting PSCA
|
MA45489A
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
|
CN108474002B
(en)
|
2015-10-22 |
2023-05-23 |
朱诺治疗学有限公司 |
Method, reagent cartridge, reagent and device for transduction
|
MA45488A
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
CELL CULTURE PROCESSES, KITS AND APPARATUS
|
CA3003678A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Children's National Medical Center |
Generating hpv antigen-specific t cells from a naive t cell population
|
EA201891066A1
(en)
|
2015-10-30 |
2018-10-31 |
ЭнБиИ-ТЕРАПЬЮТИКС АГ |
ANTIBODIES TO ROR1
|
KR20180083874A
(en)
*
|
2015-11-04 |
2018-07-23 |
사울 제이. 프라이스맨 |
The chimeric antigen receptor targeting HER2
|
MA44314A
(en)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA43378A
(en)
|
2015-12-03 |
2018-10-10 |
Juno Therapeutics Inc |
COMPOSITIONS AND METHODS FOR REDUCTION OF IMMUNE RESPONSE AGAINST CHEMERIC ANTIGEN RECEPTORS
|
MX2018006789A
(en)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Modified chimeric receptors and related compositions and methods.
|
EP4012415A3
(en)
|
2015-12-04 |
2022-12-07 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
EP3393504A1
(en)
|
2015-12-22 |
2018-10-31 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
MX2018008106A
(en)
|
2015-12-30 |
2019-03-14 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy.
|
TW201740958A
(en)
*
|
2016-01-15 |
2017-12-01 |
依圖比克斯公司 |
Methods and compositions for T-cell immunotherapy
|
CN106978442B
(en)
*
|
2016-01-18 |
2020-06-19 |
爱康得生物医学技术(苏州)有限公司 |
Preparation method of chimeric antigen receptor T cell
|
AU2017210327A1
(en)
|
2016-01-20 |
2018-08-09 |
Nbe-Therapeutics Ag |
ROR1 antibody compositions and related methods
|
EP3411408B1
(en)
|
2016-02-02 |
2021-12-08 |
Fred Hutchinson Cancer Research Center |
Anti-ror1 antibodies and uses thereof
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
MA43758A
(en)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
METHODS FOR DETERMINING THE DOSAGE OF A THERAPEUTIC AGENT AND RELATED TREATMENTS
|
US20190355459A1
(en)
|
2016-03-16 |
2019-11-21 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
DK3430038T3
(en)
|
2016-03-18 |
2021-09-13 |
Hutchinson Fred Cancer Res |
COMPOSITIONS AND PROCEDURES FOR CD20 IMMUNTERAPHY
|
WO2017165571A1
(en)
|
2016-03-22 |
2017-09-28 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
KR20190006952A
(en)
*
|
2016-03-31 |
2019-01-21 |
라이언 티씨알 피티이. 리미티드 |
Non-activated T cells expressing an exogenous virus-specific T cell receptor (TCR)
|
PL3443096T3
(en)
|
2016-04-15 |
2023-06-19 |
Novartis Ag |
Compositions and methods for selective expression of chimeric antigen receptors
|
US11963980B2
(en)
|
2016-04-25 |
2024-04-23 |
Musc Foundation For Research Development |
Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
|
CA3022611A1
(en)
|
2016-05-06 |
2017-11-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
EP3464323B1
(en)
|
2016-05-27 |
2021-09-22 |
Aadigen, LLC |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
JP2019517518A
(en)
|
2016-06-03 |
2019-06-24 |
メモリアル スローン ケタリング キャンサー センター |
Adoptive cell therapy as an early treatment option
|
MA45341A
(en)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
METHODS FOR TREATING B-LYMPHOCYTE MALIGNITIES USING ADOPTIVE CELL THERAPY
|
EP3463396A1
(en)
*
|
2016-06-07 |
2019-04-10 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
CN107522786A
(en)
*
|
2016-06-20 |
2017-12-29 |
深圳市体内生物医药科技有限公司 |
A kind of molecule, the cell for expressing it and its production and use
|
WO2017221850A1
(en)
*
|
2016-06-21 |
2017-12-28 |
国立大学法人名古屋大学 |
Adapter molecule for improvement of t-cell function
|
MA45455A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
PROCESS FOR IDENTIFYING PEPTIDIC EPITOPES, MOLECULES THAT BIND TO SUCH EPITOPES AND ASSOCIATED USES
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
EP3484516A4
(en)
*
|
2016-07-14 |
2020-03-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
CA3031734A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies against anti-cd19 antibodies
|
CN110087672A
(en)
|
2016-07-29 |
2019-08-02 |
朱诺治疗学股份有限公司 |
Immunoloregulation polypeptide and compositions related and method
|
AU2017301881A1
(en)
|
2016-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
CN110267677A
(en)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
Use the Chimeric antigen receptor treating cancer combined with former M2 macrophage molecule inhibitor
|
JP7109789B2
(en)
|
2016-08-02 |
2022-08-01 |
ティーシーアール2 セラピューティクス インク. |
Compositions and methods for TCR reprogramming using fusion proteins
|
MA46194A
(en)
|
2016-09-12 |
2019-07-17 |
Juno Therapeutics Inc |
INFUSION BIOREACTOR POCKET SETS
|
MX2019003176A
(en)
|
2016-09-23 |
2019-07-04 |
Hutchinson Fred Cancer Res |
Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof.
|
JP2019536471A
(en)
|
2016-09-27 |
2019-12-19 |
セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. |
Chimeric engulfment receptor molecule
|
EP4353319A2
(en)
|
2016-09-28 |
2024-04-17 |
Atossa Therapeutics, Inc. |
Methods of adoptive cell therapy
|
MA46354A
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics Inc |
MOLECULES BINDING SPECIFICALLY TO HPV
|
CA3039646A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
DK3445787T3
(en)
|
2016-10-07 |
2021-03-01 |
Tcr2 Therapeutics Inc |
COMPOSITIONS AND PROCEDURES FOR PROGRAMMING T-CELL RECEPTORS USING FUSION PROTEINS
|
JP2019533676A
(en)
|
2016-10-13 |
2019-11-21 |
ジュノー セラピューティクス インコーポレイテッド |
Immunotherapy methods and compositions comprising tryptophan metabolic pathway modulators
|
JP7181862B2
(en)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
Tumor-infiltrating lymphocytes and methods of treatment
|
WO2018081448A1
(en)
|
2016-10-26 |
2018-05-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modified immunoglobulin hinge regions to reduce hemagglutination
|
WO2018093591A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
EP3534938A2
(en)
*
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
JP7291396B2
(en)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
Compositions and methods for TCR reprogramming using fusion proteins
|
CN110494565A
(en)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
It is engineered B cell and compositions related and method
|
EP4279136A3
(en)
|
2016-12-03 |
2024-03-20 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
AU2017368331A1
(en)
|
2016-12-03 |
2019-06-13 |
Acerta Pharma B.V. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
AU2017368332A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for modulation of CAR-T cells
|
WO2018106732A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
MX2019006631A
(en)
|
2016-12-12 |
2019-11-12 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells.
|
US10183993B2
(en)
*
|
2017-01-09 |
2019-01-22 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
MX2019008227A
(en)
|
2017-01-10 |
2020-08-17 |
Juno Therapeutics Inc |
Epigenetic analysis of cell therapy and related methods.
|
EP3568416A4
(en)
*
|
2017-01-13 |
2020-07-08 |
Celdara Medical, LLC |
Chimeric antigen receptors targeting tim-1
|
WO2018134824A1
(en)
|
2017-01-18 |
2018-07-26 |
Yeda Research And Development Co. Ltd. |
Genetically modified veto cells and use of same in immunotherapy
|
US20190350980A1
(en)
*
|
2017-01-18 |
2019-11-21 |
Drk Blutspendedienst Baden-W?Rttemberg-Hessen Gmbh |
Compositions and methods for transplant recipient conditioning
|
WO2018134691A2
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
RU2674894C2
(en)
*
|
2017-01-30 |
2018-12-13 |
Общество с ограниченной ответственностью "ПЛАНТА" |
New luciferases and methods of their use
|
WO2018148224A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
IL268349B1
(en)
|
2017-02-17 |
2024-04-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
EP4353818A2
(en)
|
2017-02-27 |
2024-04-17 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
US20200077644A1
(en)
|
2017-03-14 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
KR102609624B1
(en)
|
2017-03-15 |
2023-12-05 |
옥스포드 바이오메디카(유케이) 리미티드 |
method
|
WO2018170338A2
(en)
|
2017-03-15 |
2018-09-20 |
Fred Hutchinson Cancer Research Center |
High affinity mage-a1-specific tcrs and uses thereof
|
CN110832075A
(en)
|
2017-03-22 |
2020-02-21 |
诺华股份有限公司 |
Compositions and methods for immunooncology
|
CA3056261A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
US11796534B2
(en)
|
2017-04-14 |
2023-10-24 |
Juno Therapeutics, Inc. |
Methods for assessing cell surface glycosylation
|
MX2019011897A
(en)
|
2017-04-18 |
2019-11-28 |
Fujifilm Cellular Dynamics Inc |
Antigen-specific immune effector cells.
|
NZ758485A
(en)
|
2017-04-27 |
2024-02-23 |
Juno Therapeutics Gmbh |
Oligomeric particle reagents and methods of use thereof
|
SG11201910143TA
(en)
|
2017-05-01 |
2019-11-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
US11851649B2
(en)
|
2017-05-17 |
2023-12-26 |
Seattle Children's Hospital |
Generating mammalian T cell activation inducible synthetic promoters (SYN+PRO) to improve T cell therapy
|
WO2018218038A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
JP7158416B2
(en)
|
2017-05-24 |
2022-10-21 |
イーフェクター セラピューティクス, インコーポレイテッド |
Compositions and methods for improving anti-tumor immune responses
|
CA3065120A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
AU2018275891A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
EP3828264A1
(en)
|
2017-06-20 |
2021-06-02 |
Institut Curie |
Immune cells defective for suv39h1
|
KR20200019231A
(en)
|
2017-06-22 |
2020-02-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Method for producing regulatory immune cells and uses thereof
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
JP2020530307A
(en)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
Adeno-associated virus vector for gene therapy
|
GB201710836D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
GB201710835D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Antibodies
|
CN111246861A
(en)
|
2017-07-29 |
2020-06-05 |
朱诺治疗学股份有限公司 |
Reagent for amplifying cell expressing recombinant receptor
|
SG11202000846WA
(en)
|
2017-08-07 |
2020-02-27 |
Nbe Therapeutics Ag |
Anthracycline-based antibody drug conjugates having high in vivo tolerability
|
MX2020001491A
(en)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Methods and compositions for preparing genetically engineered cells.
|
MX2020001490A
(en)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Methods for producing genetically engineered cell compositions and related compositions.
|
MA50057A
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics Inc |
GENE EXPRESSION AND ASSESSMENT OF A RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY
|
KR20200041377A
(en)
|
2017-09-06 |
2020-04-21 |
프레드 헛친슨 켄서 리서치 센터 |
STREP-TAG specific binding protein and its use
|
AU2018327225A1
(en)
|
2017-09-06 |
2020-02-27 |
Fred Hutchinson Cancer Center |
Strep-tag specific chimeric receptors and uses thereof
|
US20210106618A1
(en)
|
2017-09-06 |
2021-04-15 |
Fred Hutchinson Cancer Research Center |
Methods for improving adoptive cell therapy
|
WO2019051335A1
(en)
|
2017-09-07 |
2019-03-14 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
CN109517820B
(en)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
gRNA of target HPK1 and HPK1 gene editing method
|
CN107641615A
(en)
*
|
2017-09-22 |
2018-01-30 |
苏州大学 |
The immunocyte separation method of infiltration in a kind of mice pancreatic
|
US11708423B2
(en)
|
2017-09-26 |
2023-07-25 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
MA50613A
(en)
|
2017-10-03 |
2020-08-12 |
Editas Medicine Inc |
HPV-SPECIFIC BINDING MOLECULES
|
CN107759699A
(en)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
Target transgenic T cells of CD30 antigens and preparation method and application
|
KR20200096758A
(en)
|
2017-10-18 |
2020-08-13 |
인트렉손 코포레이션 |
Polypeptide composition comprising a spacer
|
WO2019079777A1
(en)
|
2017-10-20 |
2019-04-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
MA49911A
(en)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO THE B-LYMPHOCYTE MATURATION ANTIGEN
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
SG11202003688PA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Process for generating therapeutic compositions of engineered cells
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
CA3082010A1
(en)
*
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
SG11202003862PA
(en)
|
2017-11-01 |
2020-05-28 |
Editas Medicine Inc |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
JP7258899B2
(en)
|
2017-11-01 |
2023-04-17 |
ジュノー セラピューティクス インコーポレイテッド |
Methods for making T cell compositions
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
WO2019090110A1
(en)
*
|
2017-11-03 |
2019-05-09 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-ror1 immunotherapy
|
WO2019090364A1
(en)
|
2017-11-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
CN111556893A
(en)
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
Methods, compositions, and components for CRISPR-CAS9 editing of CBLB in immunotherapy T cells
|
MX2020004801A
(en)
*
|
2017-11-09 |
2020-08-13 |
Medimmune Llc |
Bispecific fusion polypeptides and methods of use thereof.
|
JP2021502094A
(en)
|
2017-11-10 |
2021-01-28 |
ジュノー セラピューティクス インコーポレイテッド |
Closed cryogenic container
|
KR20200080270A
(en)
|
2017-11-10 |
2020-07-06 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Chimeric antigen receptor targeting tumor antigen
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
WO2019098682A1
(en)
*
|
2017-11-14 |
2019-05-23 |
앱클론(주) |
Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
WO2019109047A1
(en)
|
2017-12-01 |
2019-06-06 |
Fred Hutchinson Cancer Research Center |
Binding proteins specific for 5t4 and uses thereof
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
CN112203680A
(en)
|
2017-12-08 |
2021-01-08 |
朱诺治疗学股份有限公司 |
Phenotypic markers for cell therapy and related methods
|
US20210207080A1
(en)
|
2017-12-08 |
2021-07-08 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
MA51114A
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics Inc |
PROCESS FOR PRODUCING A COMPOSITIONS OF MODIFIED T-LYMPHOCYTES
|
US20210070845A1
(en)
|
2017-12-15 |
2021-03-11 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
WO2019126358A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
CN109971837A
(en)
*
|
2017-12-28 |
2019-07-05 |
上海细胞治疗研究院 |
A kind of detection method and kit of exogenous antibodies gene copy number
|
US11919937B2
(en)
|
2018-01-09 |
2024-03-05 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
WO2019140278A1
(en)
|
2018-01-11 |
2019-07-18 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting core binding factor antigens
|
CN112055595A
(en)
|
2018-01-22 |
2020-12-08 |
恩多塞特公司 |
Methods of use of CAR T cells
|
CN111918972A
(en)
|
2018-01-31 |
2020-11-10 |
朱诺治疗学股份有限公司 |
Methods and reagents for assessing the presence or absence of replication competent viruses
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
CN111936518A
(en)
*
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Fluorescein-specific CARs exhibiting optimal T cell function for FL-PLE labeled tumors
|
SG11202007660UA
(en)
|
2018-02-12 |
2020-09-29 |
Hutchinson Fred Cancer Res |
Cyclin a1 specific t cell receptors and uses thereof
|
AU2019224051A1
(en)
|
2018-02-26 |
2020-09-03 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
US10751399B2
(en)
*
|
2018-03-20 |
2020-08-25 |
Cho Pharma Usa, Inc. |
Chimeric antigen receptors that bind to SSEA4 and uses thereof
|
RU2020135106A
(en)
|
2018-03-28 |
2022-04-29 |
Серо Терапьютикс, Инк. |
EXPRESSION VECTORS FOR CHIMERIC UPCOMATION RECEPTORS, GENETICALLY MODIFIED HOST CELLS AND THEIR APPLICATIONS
|
MX2020010241A
(en)
|
2018-03-28 |
2020-10-16 |
Cero Therapeutics Inc |
Cellular immunotherapy compositions and uses thereof.
|
US20210015865A1
(en)
|
2018-03-28 |
2021-01-21 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
EP3774906A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
KR20210020873A
(en)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Τ cells expressing recombinant receptors, related polynucleotides and methods
|
PE20201345A1
(en)
|
2018-04-05 |
2020-11-25 |
Juno Therapeutics Inc |
RECEIVERS OF T-CELLS, AND DESIGNED CELLS THAT EXPRESS THEM
|
WO2019200347A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Fred Hutchinson Cancer Research Center |
Methods for adoptive cell therapy targeting ror1
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
BR112020022185A2
(en)
|
2018-05-03 |
2021-02-02 |
Juno Therapeutics Inc |
combination therapy of a chimeric antigen (car) receptor t cell therapy and a kinase inhibitor
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
CN108441505B
(en)
*
|
2018-05-28 |
2023-07-07 |
上海恒润达生生物科技股份有限公司 |
Chimeric antigen receptor targeting ROR1 and application thereof
|
US20210223248A1
(en)
|
2018-06-01 |
2021-07-22 |
Fred Hutchinson Cancer Research Center |
Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
|
EP3802825A1
(en)
|
2018-06-08 |
2021-04-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
JP7438988B2
(en)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
BCMA chimeric antigen receptor and its use
|
AR116109A1
(en)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
|
WO2020018964A1
(en)
|
2018-07-20 |
2020-01-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for controlled expression of antigen-specific receptors
|
SG11202101204TA
(en)
|
2018-08-09 |
2021-03-30 |
Juno Therapeutics Inc |
Processes for generating engineered cells and compositions thereof
|
CA3108698A1
(en)
|
2018-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
JP2021534130A
(en)
*
|
2018-08-10 |
2021-12-09 |
ユーティレックス カンパニー リミテッド |
Cancer antigen-specific cytotoxic T cells
|
JP2021534784A
(en)
*
|
2018-08-31 |
2021-12-16 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
Methods and Compositions Containing B7H3 Chimeric Antigen Receptor
|
KR20210112295A
(en)
|
2018-08-31 |
2021-09-14 |
잉벡띠스 에스아 |
Chimeric antigen receptors for multiple HLA-G isoforms
|
SG11202102108QA
(en)
|
2018-09-11 |
2021-04-29 |
Juno Therapeutics Inc |
Methods for mass spectrometry analysis of engineered cell compositions
|
WO2020056170A1
(en)
|
2018-09-12 |
2020-03-19 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
WO2020068702A1
(en)
|
2018-09-24 |
2020-04-02 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
NL2021789B1
(en)
|
2018-10-10 |
2020-05-14 |
Academisch Ziekenhuis Leiden |
Binding proteins specific for HA-1H and uses thereof
|
EP3873482A4
(en)
*
|
2018-10-31 |
2022-12-14 |
Bellicum Pharmaceuticals, Inc. |
T cells with suicide switch
|
KR20210098450A
(en)
|
2018-10-31 |
2021-08-10 |
주노 테라퓨틱스 게엠베하 |
Method for cell selection and stimulation and device therefor
|
CN113614108A
(en)
*
|
2018-11-01 |
2021-11-05 |
朱诺治疗学股份有限公司 |
G-protein coupled receptor class C group 5member D (GPRC5D) specific chimeric antigen receptor
|
US20210393690A1
(en)
|
2018-11-01 |
2021-12-23 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
AU2019374790A1
(en)
|
2018-11-06 |
2021-05-27 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered T cells
|
SG11202104411VA
(en)
|
2018-11-08 |
2021-05-28 |
Juno Therapeutics Inc |
Methods and combinations for treatment and t cell modulation
|
WO2020102770A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
CA3121027A1
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
EP3886874A1
(en)
|
2018-11-29 |
2021-10-06 |
Board of Regents, The University of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
WO2020113188A2
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
KR20210117260A
(en)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Treatment using adoptive cell therapy
|
CN113286875A
(en)
*
|
2018-12-19 |
2021-08-20 |
Inserm(法国国家健康医学研究院) |
Mucosal-associated invariant T (MAIT) cells expressing chimeric antigen receptors
|
MX2021007392A
(en)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives.
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
MX2021009763A
(en)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof.
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CA3130618A1
(en)
|
2019-02-20 |
2020-08-27 |
Fred Hutchinson Cancer Research Center |
Binding proteins specific for ras neoantigens and uses thereof
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
JP2022533128A
(en)
|
2019-05-16 |
2022-07-21 |
ユニバーシティ オブ ワシントン |
LOCKR-mediated recruitment of CAR T cells
|
AU2020287882A1
(en)
|
2019-06-07 |
2022-01-20 |
Juno Therapeutics, Inc. |
Automated T cell culture
|
EP3983006A1
(en)
|
2019-06-12 |
2022-04-20 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
CN114222763A
(en)
*
|
2019-06-19 |
2022-03-22 |
尤利乌斯·马克西米利安维尔茨堡大学 |
Supermodular IgG3 spacer domain and multifunctional sites achieved in chimeric antigen receptor design
|
BR112021026832A2
(en)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Recombinant ad35 vectors and related gene therapy enhancements
|
JP2022542051A
(en)
*
|
2019-07-23 |
2022-09-29 |
ウェン ヤン, |
Compositions and methods for adoptive immunotherapy
|
AU2020318781A1
(en)
|
2019-07-23 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immune cells defective for SUV39H1
|
KR20220066892A
(en)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Combination therapy of T cell therapy and Zest homologue 2 enhancer (EH2) inhibitor and related methods
|
EP4022637A2
(en)
|
2019-08-30 |
2022-07-06 |
Juno Therapeutics, Inc. |
Machine learning methods for classifying cells
|
EP4025244A1
(en)
|
2019-09-02 |
2022-07-13 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
EP4028523A1
(en)
|
2019-09-09 |
2022-07-20 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
US20220356246A1
(en)
*
|
2019-09-27 |
2022-11-10 |
Nanjing Immunophage Biotech Co.,Ltd. |
Anti-ROR1 antibodies and preparation method and uses thereof
|
EP4038097A1
(en)
|
2019-10-03 |
2022-08-10 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2021078910A1
(en)
|
2019-10-22 |
2021-04-29 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
MX2022005145A
(en)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use.
|
KR20220131892A
(en)
|
2019-11-05 |
2022-09-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Methods for determining the properties of therapeutic T-cell compositions
|
JP2022554353A
(en)
|
2019-11-07 |
2022-12-28 |
ジュノー セラピューティクス インコーポレイテッド |
T cell therapy and (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6- Combination with Dione
|
AU2020395318A1
(en)
|
2019-12-06 |
2022-06-09 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
|
KR20220122656A
(en)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-idiotypic Antibodies and Related Compositions and Methods Against GPDAC5D-Targeting Binding Domain
|
CA3163897A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
AU2020406350A1
(en)
|
2019-12-20 |
2022-08-11 |
Novartis Ag |
Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
BR112022014501A2
(en)
|
2020-01-24 |
2022-09-20 |
Juno Therapeutics Inc |
METHODS FOR DOSING AND TREATMENT OF FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA IN ADOPTIVE CELL THERAPY
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
CA3170153A1
(en)
|
2020-02-12 |
2021-08-19 |
Juno Therapeutics, Inc. |
Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
AU2021220875A1
(en)
|
2020-02-12 |
2022-09-29 |
Juno Therapeutics, Inc. |
CD19-directed chimeric antigen receptor T cell compositions and methods and uses thereof
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
CN113402612A
(en)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
|
IL297147A
(en)
|
2020-04-10 |
2022-12-01 |
Juno Therapeutics Inc |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
AU2021263765A1
(en)
|
2020-04-28 |
2022-12-01 |
Juno Therapeutics, Inc. |
Combination of BCMA-directed T cell therapy and an immunomodulatory compound
|
US20230212243A1
(en)
|
2020-05-12 |
2023-07-06 |
Institut Curie |
Neoantigenic Epitopes Associated with SF3B1 Mutations
|
EP4149968A1
(en)
*
|
2020-05-12 |
2023-03-22 |
Lyell Immunopharma, Inc. |
Chimeric antigen receptor spacers
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
EP4153301A2
(en)
|
2020-05-21 |
2023-03-29 |
Board of Regents, The University of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021235894A1
(en)
*
|
2020-05-22 |
2021-11-25 |
Green Cross Lab Cell Corporation |
Anti-HER2 Antibody or Antigen-binding Fragment thereof, and Chimeric Antigen Receptor Comprising Same
|
JP2023529211A
(en)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
ZBTB32 inhibitors and uses thereof
|
JP2023531676A
(en)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
Dosing Regimens Containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives
|
KR20230042283A
(en)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
Engineered T cells conditionally expressing recombinant receptors, related polynucleotides and methods
|
JP2023535371A
(en)
|
2020-07-17 |
2023-08-17 |
シミュレックス インコーポレイテッド |
Chimeric MyD88 Receptors and Related Compositions and Methods for Redirecting Immunosuppressive Signaling
|
EP4188395A1
(en)
|
2020-07-30 |
2023-06-07 |
Institut Curie |
Immune cells defective for socs1
|
CN116134027A
(en)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof
|
JP2023536326A
(en)
|
2020-08-05 |
2023-08-24 |
ジュノー セラピューティクス インコーポレイテッド |
Anti-idiotypic antibodies against ROR1 target binding domains and related compositions and methods
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
CN112111014A
(en)
*
|
2020-09-22 |
2020-12-22 |
廖文强 |
Antioxidant chimeric antigen receptor and immune cell
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
JP2023542528A
(en)
|
2020-09-24 |
2023-10-10 |
フレッド ハッチンソン キャンサー センター |
Immunotherapy targeting SOX2 antigen
|
NL2026614B1
(en)
|
2020-10-02 |
2022-06-03 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against bob1 and uses thereof
|
TW202222841A
(en)
|
2020-10-06 |
2022-06-16 |
福瑞德哈金森腫瘤研究中心 |
Compositions and methods for treating mage-a1-expressing disease
|
KR20230090367A
(en)
|
2020-11-04 |
2023-06-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cells Expressing Chimeric Receptors from Modified Invariant CD3 Immunoglobulin Superfamily Chain Loci and Related Polynucleotides and Methods
|
MX2023005234A
(en)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies.
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
US20220195396A1
(en)
*
|
2020-12-03 |
2022-06-23 |
Century Therapeutics, Inc. |
Genetically Engineered Cells and Uses Thereof
|
CN112481284B
(en)
*
|
2020-12-07 |
2023-07-25 |
深圳瑞吉生物科技有限公司 |
mRNA (messenger ribonucleic acid) encoding CAR (CAR-T) gene, combined mRNA, construction method, CAR-T cell and application
|
AU2021397206A1
(en)
*
|
2020-12-08 |
2023-07-27 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Anti-egfr chimeric antigen receptors
|
CA3201767A1
(en)
|
2020-12-14 |
2022-06-23 |
Thomas M. Schmitt |
Compositions and methods for cellular immunotherapy
|
CN117222880A
(en)
|
2020-12-16 |
2023-12-12 |
朱诺治疗学股份有限公司 |
Threshold gating for flow cytometry methods
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
TW202242121A
(en)
|
2021-01-11 |
2022-11-01 |
美商薩那生物科技公司 |
Use of cd8-targeted viral vectors
|
JP2024510898A
(en)
*
|
2021-02-25 |
2024-03-12 |
ライエル・イミュノファーマ・インコーポレイテッド |
Chimeric antigen receptor targeting ROR1
|
AU2022227021A1
(en)
|
2021-02-26 |
2023-09-21 |
Kelonia Therapeutics, Inc. |
Lymphocyte targeted lentiviral vectors
|
JP2024509853A
(en)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Combination of T cell therapy and DGK inhibitor
|
WO2022189620A1
(en)
|
2021-03-11 |
2022-09-15 |
Institut Curie |
Transmembrane neoantigenic peptides
|
IL305809A
(en)
|
2021-03-11 |
2023-11-01 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
KR20230172630A
(en)
|
2021-03-11 |
2023-12-22 |
므네모 테라퓨틱스 |
Tumor Neoantigenic Peptide
|
CA3208944A1
(en)
|
2021-03-22 |
2022-09-29 |
Edith NALBANDIAN |
Method to assess potency of viral vector particles
|
CA3210581A1
(en)
|
2021-03-22 |
2022-09-29 |
Neil HAIG |
Methods of determining potency of a therapeutic cell composition
|
AU2022252220A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
AU2022246593A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
TW202304979A
(en)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
JP2024517413A
(en)
|
2021-04-16 |
2024-04-22 |
セルジーン コーポレーション |
T-Cell Therapy in Patients Who Have Previously Undergone Stem Cell Transplantation
|
JP2024514163A
(en)
|
2021-04-16 |
2024-03-28 |
セルジーン コーポレーション |
Combination therapy using BCMA-directed T cell therapy
|
CN113735978B
(en)
*
|
2021-04-22 |
2023-06-30 |
河北森朗生物科技有限公司 |
Chimeric antigen receptor targeting CD19, preparation method and application thereof
|
JP2024517863A
(en)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Methods for stimulating and transducing cells
|
WO2023288281A2
(en)
|
2021-07-15 |
2023-01-19 |
Fred Hutchinson Cancer Center |
Chimeric polypeptides
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
WO2023015217A1
(en)
|
2021-08-04 |
2023-02-09 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
AU2022330106A1
(en)
|
2021-08-16 |
2024-03-21 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
TW202342498A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae fusion glycoproteins
|
TW202342757A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae attachment glycoproteins
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023139269A1
(en)
|
2022-01-21 |
2023-07-27 |
Mnemo Therapeutics |
Modulation of suv39h1 expression by rnas
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150801A2
(en)
*
|
2022-02-07 |
2023-08-10 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
|
NL2030990B1
(en)
|
2022-02-17 |
2023-09-01 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against jchain and uses thereof
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
NL2031118B1
(en)
|
2022-03-01 |
2023-09-07 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against transcription factor wt1 and uses thereof
|
WO2023178348A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023225569A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
WO2023235819A1
(en)
*
|
2022-06-01 |
2023-12-07 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Recombinant receptors binding b cell activation factor receptor and uses thereof
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
NL2032130B1
(en)
|
2022-06-10 |
2023-12-18 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against melanoma-associated antigen and uses thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|